Why the study?
Noroviruses are the main cause of acute viral gastroenteritis worldwide, but no vaccine or specific antiviral treatment is available.
2'-FdC demonstrates significant antiviral activity against murine norovirus in vitro, with synergistic effects when combined with other antivirals, suggesting potential for drug development.
2'-FdC inhibits murine norovirus in macrophages; leaves open antiviral development for human norovirus.
Noroviruses are the main causative agents of acute viral gastroenteritis worldwide. However, no vaccine or specific antiviral treatment is available, imposing a heavy global health burden. The nucleoside analogue 2'-fluoro-2'-deoxycytidine (2'-FdC) has been reported to have broad antiviral activity. Here, we report that 2'-FdC significantly inhibits murine norovirus replication in macrophages. This effect was partially reversed by exogenous supplementation of cytidine triphosphate. The combination of 2'-FdC with mycophenolic acid, ribavirin or favipiravir (T705) exerts synergistic antiviral effects. These results indicate that 2'-FdC is a potential candidate for antiviral drug development against norovirus infection.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: